XOMA and Pfizer Partner, XOMA Up 24% in Pre-Market
This morning pre-market trading was off to a strong start for XOMA Ltd. (Nasdaq: XOMA). By 7:30 a.m. CDT the stock was up 24 percent to $2.82 per share with a volume of 267,000. Before market open XOMA shares saw a gain of 54 cents from Monday’s closing price per share of $2.28. The activity in the pre-market came right as the company announced the licensing of its patented bacterial cell expression (BCE) technology to Pfizer. Bacterial cell expression is an technology used to discover, develop and manufacture recombiant antibodies for commercial uses. According to XOMA, Pfizer is paying $30…